ABOUT THIS DESK
A Reading Room, Not a Pharmacy
Why Peptide Asia exists, how it decides what to say about a study, and where its editorial line sits.
What this site is
Peptide Asia is an independent literature digest. It exists to answer one recurring question honestly: for a given research peptide, what does the published evidence actually show, and how far does it actually reach? It is not a clinic, not a pharmacy, and not a vendor of any kind. Nothing on this site is for sale, and nothing on it is a substitute for a conversation with a qualified clinician.
The site was built around a specific observation: discussions of research peptides online tend to flatten a genuinely important distinction — the gap between a compound that is an approved medicine somewhere and one that has never been approved anywhere, and the corresponding gap in how much reliable human evidence exists for each. Four peptides sit on this desk precisely because they illustrate that spectrum clearly: semaglutide, a fully approved drug with a dense trial record; thymosin alpha-1, approved abroad but not in the United States; and BPC-157 and MOTS-c, neither approved anywhere, with human evidence that ranges from thin to essentially nonexistent.
How this site reads a study
Every quantitative claim on this site is traced to a specific study, review, or trial and cited by number against a shared reference list on the references page. Where a finding comes from animal or cell research, that is stated explicitly rather than implied to be human data. Where community reports describe an effect that has not been formally studied, it is labeled as anecdotal, not clinical evidence, and never paired with a specific dose.
This site also tries to hold two things in tension that are often collapsed into one: regulatory approval and evidence quality. A compound can be unapproved and still have a coherent, peer-reviewed mechanism behind it; a compound can be approved and still turn up an inconvenient result in its own trials, as happened when semaglutide lost a head-to-head comparison to a newer agent, and again when thymosin alpha-1's largest sepsis trial came back null despite decades of favourable clinical use abroad. Neither approval status nor popularity is treated here as a stand-in for what a study actually found.
What this site will not do
It will not recommend a dose for a person to take, for any compound, under any circumstance. It will not present an animal finding as though it were established in humans. It will not describe a compound's legal or regulatory status inaccurately to make a point read more cleanly. And it will not manufacture certainty where the literature has none — as with MOTS-c, where the honest answer to several common questions is simply that no human interventional trial yet exists.
If a claim on this site cannot be traced to a citation, it should not be there. Readers who spot one are encouraged to treat it as an error, because that is what it would be.